Immunovant (IMVT) Current Assets (2018 - 2026)

Immunovant has reported Current Assets for 9 years, with the latest figure at $948.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 23.6% year-over-year to $948.8 million; the trailing twelve-month figure through Mar 2026 stood at $948.8 million (up 23.6% YoY), and the FY2026 full-year result was $948.8 million, up 23.6% from the prior year.
• Current Assets for Q1 2026 stood at $948.8 million, down from $1.0 billion in the prior quarter.
• The five-year high for Current Assets was $1.0 billion in Q4 2025, with the low at $291.2 million in Q3 2023.
• Historically, Current Assets has averaged $574.4 million across 5 years, with a median of $512.9 million in 2022.
• Annual changes were most pronounced in 2024 — Current Assets plunged 41.96% — and 2025, when it jumped 152.81%.
• Immunovant's Current Assets stood at $454.4 million in 2022, then surged by 56.41% to $710.8 million in 2023, then sank by 41.96% to $412.5 million in 2024, then jumped by 152.81% to $1.0 billion in 2025, then dropped by 9.02% to $948.8 million in 2026.
• The last three Current Assets figures came in at $948.8 million (Q1 2026), $1.0 billion (Q4 2025), and $573.5 million (Q3 2025), per Business Quant data.